Brief: Appili Therapeutics Expands Ati-1501 Commercial Agreement With Partner Saptalis Pharmaceuticals
08/02/2022 12:30
Feb 8 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS EXPANDS ATI-1501 COMMERCIAL AGREEMENT
WITH
PARTNER SAPTALIS PHARMACEUTICALS
* APPILI THERAPEUTICS INC - AGREEMENT EXPANDED TO ADD
EUROPEAN AND
LATIN AMERICAN MARKETS
* APPILI THERAPEUTICS INC - NDA FILING WITH US FDA FOR
APPILI'S
ATI-1501 EXPECTED LATER THIS YEAR
* APPILI THERAPEUTICS INC - NDA FILING WITH US FDA FOR
APPILI'S
ATI-1501 EXPECTED LATER THIS YEAR
Source text for Eikon: ID:nBw5P3Xxda
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez